Clarus Therapeutics to Report Third Quarter 2021 Financial and Operating Results
Clarus Therapeutics to Report Third Quarter 2021 Financial and Operating Results
NORTHBROOK, Ill., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. ("Clarus") (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced it will release its third quarter 2021 financial and operating results on Thursday, November 18, 2021, after the market closes.
亞洲網伊利諾伊州諾斯布魯克11月17日電克拉魯斯治療控股公司(“克拉魯斯”)(納斯達克代碼：CRXT)今天宣佈，它將在2021年11月18日(星期四)市場收盤後公佈2021年第三季度的財務和經營業績。該公司致力於通過推進男性和女性的雄激素和代謝療法來為未得到滿足的醫療需求提供解決方案。
Clarus will host a conference call on Thursday, November 18, 2021, at 5:15 p.m. ET to discuss the results. The dial-in numbers are (844) 249-2007 for domestic callers and (224) 619-3902 for international callers. The conference ID number is 1354439. A live webcast and replay of the conference call will be accessible through the Investors section of Clarus Therapeutics' website at Investors.ClarusTherapeutics.com.
Clarus將於2021年11月18日(星期四)下午5點15分主持電話會議。ET討論結果。國內來電的撥入號碼是(844)249-2007，國際來電的撥入號碼是(224)619-3902。會議ID號碼是1354439。電話會議的現場網絡直播和重播可通過Clarus治療公司網站的投資者部分收看，網址為Investors.ClarusTreeutics.com。
About Clarus Therapeutics Holdings, Inc.
Clarus Therapeutics Holdings, Inc. is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women – including potential therapies for orphan indications. Clarus Therapeutics' first commercial product is JATENZO® (testosterone undecanoate). For more information, visit www.clarustherapeutics.com and www.jatenzo.com. Follow us on Twitter (@Clarus_Thera) and LinkedIn (Clarus Therapeutics).
克拉魯斯治療控股公司簡介克拉魯斯治療控股公司是一家制藥公司，在為男性和女性開發雄激素和代謝療法方面擁有專業知識，包括針對孤兒適應症的潛在療法。Clarus Treeutics的第一個商業化產品是JATENZO®(十一酸睾酮)。欲瞭解更多信息，請訪問www.clarusTreateutics.com和www.jatenzo.com。在Twitter(@Clarus_Thera)和LinkedIn(Clarus Treeutics)上關注我們。
Clarus Investor Relations Contact:
Kara Stancell
kstancell@clarustherapeutics.com
(847) 562-4300 x 206
克拉魯斯投資者關係部聯繫人：卡拉·斯坦塞爾郵箱：kstancell@clarusTreateutics.com(847) 562-4300 x 206